mab

Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody expressed in CHO cells, effectively competes with the virus Spike protein for binding to the CD26 receptor, thereby inhibiting viral invasion into host cells.

Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human IgG1 monoclonal antibody derived from CHO cells that effectively inhibits the interaction between the MERS-CoV spike protein and the DPP4 receptor[1].

Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody derived from CHO cells, designed to selectively bind the Spike (S1) protein, thereby preventing SARS virus infection in susceptible cells[1].

Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody produced from CHO cells, which specifically targets the S1 domain of the Spike protein in both SARS-CoV and SARS-CoV-2.

Anti-Spike-RBD mAb is a CHO cell-derived human monoclonal IgG1 antibody that potentially treats SARS-CoV-2 by blocking the interaction between the spike protein and ACE2[1].

The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the SARS-CoV-2 RBD. [1]

Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.

Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5. It induces apoptosis in various tumor types through caspase activation and can be used to study advanced solid tumors.

Elsilimomab (B-E8) is a monoclonal antibody targeting interleukin-6 (IL-6), inhibiting DNMT3A mutant clone-induced hematopoietic stromal cell senescence, used in the study of multiple myeloma and renal cell carcinoma.

Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant mesothelioma. Lexatumumab can be used to study malignant pleural mesothelioma (MPM).

Avdoralimab (IPH 5401) is a humanized monoclonal antibody targeting Complement C5a receptor 1 (C5aR1), used in research on bullous pemphigoid and chronic urticaria.

Ifabotuzumab (KB-004) is an antibody targeting EphA3+ cells, significantly reducing CCR10+ cells and improving pulmonary fibrosis in humanized NSG mice.

Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.

Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.

Tamrintamab (SC-003 mAb) is an antibody targeting dipeptidase 3 (DPEP3), a potential cytotoxic agent for ovarian cancer research.

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine composed of a humanized 14.18 anti-GD2 monoclonal antibody (mAb) linked to interleukin-2 (IL2). It exerts anti-tumor effects [1] by inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity, targeting GD2-expressing tumor cells, and stimulating NK and T cells via IL2 receptors.

MEDI-3617 is a humanized antibody targeting Ang2/ANGPT2/Angiopoietin2, inhibits loss of endothelial/smooth muscle cell contact, and can be used to study cardiovascular disease.

Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1 that specifically targets the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD), effectively neutralizing the virus by blocking its ability to bind to receptors [1].

Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. It enhances pro-apoptotic activity in vitro and mediates complement-dependent and antibody-dependent cytotoxic effects. In various tumor xenograft models, this antibody shows increased anti-tumor activity. In primate pharmacodynamics models, it exhibits excellent B cell depletion in lymphatic organs and bone marrow. It is applicable in the study of B cell malignancies.

Anti-DM1 antibody (14E3) (Rabbit mAb) is a rabbit-derived IgG antibody targeting DM1, can be used for activity assays, functional studies, binding affinity analysis, and other applications, serving as an essential tool in biological research.

MAb604.107 is a human monoclonal antibody targeting NOTCH1. It inhibits the proliferation of primary T-ALL cells and reduces CD34/CD44 expression. MAb604.107 demonstrates antitumor activity in four tumor xenograft mouse models: MDA-MB-231, HCC-1806, BT-474, and HCT-116. It can be utilized in research on T acute lymphoblastic leukemia (T-ALL).

MAB802 (MRG002 antibody) is a recombinant humanized anti-HER2 monoclonal antibody. It shares the same amino acid sequence as Trastuzumab but is highly fucosylated. The antibody-dependent cell-mediated cytotoxicity (ADCC) activity of MAB802 is comparatively lower. MAB802 is employed as the antibody component in the antibody-drug conjugate Trastuzumab vedotin (MRG002).

Anti-Human/Rat/Fish AChR Antibody (Mab35) is an IgG1 antibody inhibitor derived from rats, targeting AChR in humans, rats, and fish.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.